BACK of the BOOK
Heard in the Blogosphere
@DrMJoyner (Michael Joyner, MD)
Four problems with #PrecisionMedicine: 1) Reader’s
Digest biology 2) Bad public policy 3) Hypothesis? 4)
Big science run amok
@RichDuszak
Don’t just measure what you can measure. Measure
what matters.
@CleClinic_Matt (Matt Kalaycio, MD)
The most common medical procedure according to
my boss @TobyCosgroveMD? COMMUNICATION
@WilliamDale_MD (William Dale, MD, PhD)
Do not regret growing older. It’s a privilege denied
to many. --Anonymous #aging
@Dr_Dhawale (Tejas Dhawale, MD)
Seattle Sneakers
Racing in the Orlando Sun Drunk on runners high.
#ASHaiku15 #ASH15 @SeattleCCA
In the Age of Digital Records, Paper Still Carries
Weight
The rush to electronic information was prompted by the best
intentions. No one debates those goals; we struggle daily to
accomplish them, and often, incredibly, we succeed. We succeed
with the simple expedient of paper. Paper has become our lingua
franca, our fallback and standby. In our new digital universe, we have
peculiarly seen a retro explosion of paper. We may no longer write
paper prescriptions, but we fax or hand-deliver paper versions of
our electronic dealings routinely now. When you don’t know what
electronic language the receiver speaks (and you never do), you go with
paper.”
—Abigail Zuger, MD, in The New York Times
How the United States Could Cure
Drug-Price Insanity
@CarlSeashore
Concrete perks of high academic achievement.
#NobelPrize #notmyparkingspot
@BloodJournal
Blood EIC Dr. Bob Löwenberg and Deputy Editor Dr. Nancy
Berliner celebrate Blood’s 70th anniversary at #ASH15.
ASHClinicalNews.org
“To make sure society keeps benefiting from specialty cancer drugs, we
need to curb their soaring costs. If we link drugs’ prices to their value,
we can continue the vital quest to lengthen and improve people’s
lives. We can draw a bull’s-eye around the places where innovation is
needed most. And we can mandate that treatments be affordable for
patients. This last, vital part of the formula would require insurers to
jettison the multi-thousand-dollar co-payments they often tack on to
expensive specialty drugs. … If we want innovation, and we certainly
do, the solution to affording it lies in paying only for its value.”
—Peter B. Bach, MD, in Fortune
“We can draw a bull’s-eye
around the places where
innovation is needed
most. And we can mandate that treatments be
affordable for patients.”
ASH Clinical News
63